RECRUITING

ADAPT Study: Assessing Diet, Appetite and Physiology Throughout Weight Loss Study)

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Behavioral weight loss programs for obesity can result in weight loss and health benefits. However, behavioral weight loss often stops despite efforts to continue losing weight, this can be called an involuntarily weight loss plateau. This study investigates changes in metabolism and/or the brain that contribute to the occurrence of an involuntary weight loss plateau.

Official Title

Physiological Changes Underlying the Weight Loss Plateau in Human

Quick Facts

Study Start:2023-10-01

Study Completion:2027-07-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06174389

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 60 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT

Inclusion Criteria	Exclusion Criteria
* BMI 30.0 - 50.0 kg/m2 * Able to attend study intervention classes and study visits/assessments * Independently living with access to food preparation facilities	* Current smoker or regular use of nicotine containing products and/or cannabis * Heavy alcohol use (≥2 drinks/d for females, ≥3 drinks/d for males) or drug use * Known cognitive impairments or h/o stroke * Type 2 diabetes (known diagnosis or by screening A1c (≥6.5%)) * Medical conditions (chronic diseases, cancer, MS) or labs limiting ability to participate * Females: currently pregnant (or 6-months postpartum of full-term pregnancy) and/or current breastfeeding * Use of medications with significant effects on appetite (e.g., weight loss medications, atypical antipsychotics, stimulants) and/or chronic use of anticoagulants * History of bariatric surgery * History of eating disorder * Current participation in a formal weight loss program * Prior or current participation in a research study involving weight loss * Weight-reduced by \>10% within past year * Weight \> 330 pounds (MRI limit) * Allergy or intolerance to or unwillingness to consume study foods provided at visit * MRI contraindication (e.g., implanted metal, claustrophobia) * Do not have a phone compatible with activity tracker or access to videoconferencing platform that will be used for the dietary intervention or other appropriate technology needed to complete study procedures * Any condition(s) found by the study team and confirmed with the PI(s) that make it unsafe to participate

Inclusion Criteria

Exclusion Criteria

* BMI 30.0 - 50.0 kg/m2
* Able to attend study intervention classes and study visits/assessments
* Independently living with access to food preparation facilities

* Current smoker or regular use of nicotine containing products and/or cannabis
* Heavy alcohol use (≥2 drinks/d for females, ≥3 drinks/d for males) or drug use
* Known cognitive impairments or h/o stroke
* Type 2 diabetes (known diagnosis or by screening A1c (≥6.5%))
* Medical conditions (chronic diseases, cancer, MS) or labs limiting ability to participate
* Females: currently pregnant (or 6-months postpartum of full-term pregnancy) and/or current breastfeeding
* Use of medications with significant effects on appetite (e.g., weight loss medications, atypical antipsychotics, stimulants) and/or chronic use of anticoagulants
* History of bariatric surgery
* History of eating disorder
* Current participation in a formal weight loss program
* Prior or current participation in a research study involving weight loss
* Weight-reduced by \>10% within past year
* Weight \> 330 pounds (MRI limit)
* Allergy or intolerance to or unwillingness to consume study foods provided at visit
* MRI contraindication (e.g., implanted metal, claustrophobia)
* Do not have a phone compatible with activity tracker or access to videoconferencing platform that will be used for the dietary intervention or other appropriate technology needed to complete study procedures
* Any condition(s) found by the study team and confirmed with the PI(s) that make it unsafe to participate

Contacts and Locations

Study Contact

ADAPT Study

CONTACT

206-616-6360

uwadaptstudy@uw.edu

ADAPT Study

CONTACT

206-685-1532

uwadaptstudy@uw.edu

Principal Investigator

Ellen Schur, MD, MS

PRINCIPAL_INVESTIGATOR

University of Washington

Marian Neuhouser, PhD, RD

PRINCIPAL_INVESTIGATOR

Fred Hutch Cancer Center

Jenny Tong, MD

PRINCIPAL_INVESTIGATOR

University of Washington/VA Puget Sound

Study Locations (Sites)

Fred Hutch Cancer Center

Seattle, Washington, 98109

United States

University of Washington - South Lake Union

Seattle, Washington, 98109

United States

Collaborators and Investigators

Sponsor: University of Washington

Ellen Schur, MD, MS, PRINCIPAL_INVESTIGATOR, University of Washington
Marian Neuhouser, PhD, RD, PRINCIPAL_INVESTIGATOR, Fred Hutch Cancer Center
Jenny Tong, MD, PRINCIPAL_INVESTIGATOR, University of Washington/VA Puget Sound

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-10-01

Study Completion Date2027-07-31

Study Record Updates

Study Start Date2023-10-01

Study Completion Date2027-07-31

Terms related to this study

Keywords Provided by Researchers

Gloisis
Weight Change

Additional Relevant MeSH Terms

Obesity